Loading patent…
AssigneeSorrento Therapeutics, Inc.
InventorsEdwige GROS, Yanliang ZHANG, Heyue ZHOU, Randy GASTWIRT
Estimating the term…
There is disclosed compositions and methods relating to or derived from anti-DLL-4 antibodies. More specifically, there is disclosed fully human antibodies that bind DLL-4, DLL-4-binding fragments and derivatives of such antibodies, and DLL-4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having DLL-4 related disorders or conditions, including various inflammatory disorders and various cancers.
A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of an antibody that binds to a Delta-like 4 (DLL-4) epitope, the antibody comprising:
A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of an antibody Fab fragment that binds to a DLL-4, epitope, the Fab fragment comprising:
A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of a single chain antibody, or fragment thereof, that binds to a DLL-4 epitope, the single chain antibody comprising:
A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of an antibody that binds to a DLL-4 epitope, the antibody comprising:
A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of an antibody that binds to a DLL-4 epitope, the antibody comprising a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO. 1, 5, and 7, and further comprising a light chain.
A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of an antibody that binds to a DLL-4 epitope, the antibody comprising a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO. 2, 6, and 8, and further comprising a heavy chain.
A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of an antibody that binds to a DLL-4 epitope, wherein the antibody comprises a heavy chain/light chain variable domain sequence selected from the group consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 5/SEQ ID NO. 6, and SEQ ID NO. 7/SEQ ID NO. 8.
Dependencies are inferred from the claim text.